Curable metastatic colorectal cancer: Recommended paradigms

Current Oncology Reports

Volumn 11, Issue 3, 2009, Pages 200-208

  Berri, Richard N ^a   Abdalla, Eddie K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LIVER INJURY; LIVER METASTASIS; LIVER RESECTION; MULTIPLE CYCLE TREATMENT; NONALCOHOLIC FATTY LIVER; POSITRON EMISSION TOMOGRAPHY; RADIOFREQUENCY ABLATION; REVIEW; STEATOSIS;

COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; PATIENT SELECTION; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 65349139422     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0029-z     Document Type: Review

References (43)

1. Abdalla EK, Vauthey JN, Ellis LM, et al.: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004, 239: 818-825.
2. Aloia TA, Vauthey JN, Loyer EM, et al.: Solitary colorectal liver metastasis: Resection determines outcome. Arch Surg 2006, 141: 460-467.
3. Choti MA, Sitzmann JV, Tiburi MF, et al.: Trends in longterm survival following liver resection for hepatic colorectal metastases. Ann Surg 2002, 235: 759-766.
4. Pawlik TM, Scoggins CR, Zorzi D, et al.: Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005, 241: 715-724.
5. Strasberg SM, Dehdashti F, Siegel BA, et al.: Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: A prospective database study. Ann Surg 2001, 233: 293-299.
6. Tomlinson JS, Jarnagin WR, DeMatteo RP, et al.: Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007, 25: 4575-4580.
7. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350: 2335-2342.
8. Tournigand C, Andre T, Achille E, et al.: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004, 22: 229-237.
9. Altendorf-Hofmann A, Scheele J: A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am 2003, 12: 165-192, xi.
10. Charnsangavej C, Clary B, Fong Y, et al.: Selection of patients for resection of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 2006, 13: 1261-1268.
11. Chun YS, Vauthey JN, Ribero D, et al.: Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: Perioperative safety and survival. J Gastrointest Surg 2007, 11: 1498-1504.
12. Abdalla EK, Adam R, Bilchik AJ, et al.: Improving resectability of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 2006, 13: 1271-1280.
13. Abdalla EK, Hicks MER Vauthey JN: Portal vein embolization: rationale, technique and future prospects. Br J Surg 2001, 88: 165-175.
14. Vauthey JN, Chaoui A, Do KA, et al.: Standardized measurement of the future liver remnant prior to extended liver resection: Methodology and clinical associations. Surgery 2000, 127: 512-529.
15. Vauthey JN, Pawlik TM, Abdalla EK, et al.: Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg 2004, 239: 722-732.
16. Johnson TN, Tucker GT, Tanner MS, Rostami-Hodjegan A: Changes in liver volume from birth to adulthood: A meta-analysis. Liver Transpl 2005, 11: 1481-1493.
17. Abdalla EK, Barnett CC, Doherty D, et al.: Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 2002, 137: 675-680.
18. Ribero D, Abdalla EK, Madoff DC, et al.: Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 2007, 94: 1386-1394.
19. Vauthey JN, Palavecino M, Curley SA, Abdalla EK: Right hepatic trisectionectomy for hepatobiliary disease: Results and an appraisal of its current role. Ann Surg 2008, 248: 138-139; author reply 139-140.
20. Azoulay D, Castaing D, Smail A, et al.: Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg 2000, 231: 480-486.
21. Curley SA, Marra P, Beaty K, et al.: Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 2004, 239: 450-458.
22. Zorzi D, Mullen JT, Abdalla EK, et al.: Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg 2006, 10: 86-94.
23. Yan TD, Sim J, Black D, et al.: Systematic review on safety and efficacy of repeat hepatectomy for recurrent liver metastases from colorectal carcinoma. Ann Surg Oncol 2007, 14: 2069-2077.
24. Aloia TA, Zorzi D, Abdalla EK, Vauthey JN: Two-surgeon technique for hepatic parenchymal transection of the noncirrhotic liver using saline-linked cautery and ultrasonic dissection. Ann Surg 2005, 242: 172-177.
25. Belghiti J, GuevarA OA, Noun R, et al.: Liver hanging maneuver: a safe approach to right hepatectomy without liver mobilization. J Am Coll Surg 2001, 193: 109-111.
26. Chun YS, Abdalla EK, Zorzi D, et al.: Liver hanging maneuver improves the outcomes of complex right upper quadrant resections [abstract]. HPB Surg 2008, 9: AB-314.
27. Adam R, Delvart V, Pascal G, et al.: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: A model to predict long-term survival. Ann Surg 2004, 240: 644-657.
28. Pozzo C, Basso M, Cassano A, et al.: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004, 15: 933-939.
29. Nordlinger B, Sorbye H, Glimelius B, et al.: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008, 371: 1007-1016.
30. Vauthey JN, Pawlik TM, Ribero D, et al.: Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006, 24: 2065-2072.
31. Fernandez FG, Ritter J, Goodwin JW, et al.: Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005, 200: 845-853.
32. Nakano H, Oussoultzoglou E, Rosso E, et al.: Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 2008, 247: 118-124.
33. Ribero D, Wang H, Donadon M, et al.: Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007, 110: 2761-2767.
34. Rubbia-Brandt L, Audard V, Sartoretti P, et al.: Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004, 15: 460-466.
35. Aloia T, Sebagh M, Plasse M, et al.: Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006, 24: 4983-4990.
36. Karoui M, Penna C, Amin-Hashem M, et al.: Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 2006, 243: 1-7.
37. Parikh AA, Gentner B, Wu TT, et al.: Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 2003, 7: 1082-1088.
38. Scappaticci FA, Fehrenbacher L, Cartwright T, et al.: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005, 91: 173-180.
39. D'Angelica M, Kornprat P, Gonen M, et al.: Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: A matched case-control study. Ann Surg Oncol 2007, 14: 759-765.
40. Benoist S, Brouquet A, Penna C, et al.: Complete response of colorectal liver metastases after chemotherapy: Does it mean cure? J Clin Oncol 2006, 24: 3939-3945.
41. Tan MC, Linehan DC, Hawkins WG, et al.: Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 2007, 11: 1112-1119.
42. Adam R, Wicherts DA, de Haas RJ, et al.: Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality? J Clin Oncol 2008, 26: 1635-1641.
43. Blazer DG 3rd, Kishi Y, Maru DM, et al.: Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 2008, 26: 5344-5351.